中国医药：向专业投资者公开发行公司债券获得注册批复

Core Viewpoint - China National Pharmaceutical Group (600056.SH) has announced the approval to issue corporate bonds totaling up to 2 billion yuan to professional investors, enhancing its financial flexibility for future projects [1] Group 1: Corporate Actions - The company will hold its 2024 annual shareholders' meeting on May 16, 2025, to review and approve the proposal for the issuance of corporate bonds and short-term financing bills [1] - The China Securities Regulatory Commission has granted approval for the company to publicly issue corporate bonds with a total face value not exceeding 2 billion yuan [1] - The approval is valid for 24 months from the date of registration, allowing the company to issue the bonds in multiple tranches within this period [1]